FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387248528> ?p ?o ?g. }

• W4387248528 endingPage "A3111" @default.
• W4387248528 startingPage "A3110" @default.
• W4387248528 abstract "SESSION TITLE: Diffuse Lung Disease Posters 2 SESSION TYPE: Original Investigation Posters PRESENTED ON: 10/10/2023 12:00 pm - 12:45 pm PURPOSE: Heart involvement and interstitial lung disease (ILD) are one of the serious manifestations of systemic sclerosis (SSc) and associated with worse survival and prognosis. Nowadays there are many reports on efficacy of rituximab (RTX) therapy for ILD-SSc. At the same time, data on the combination of ILD with cardiac involvement and effect of rituximab (RTX) therapy still required. The aim of our study was to assess prevalence of cardiac complications in ILD-SSc patients (pts) and effect of RTX therapy. METHODS: This study included 103 pts with SSc. Most of the pts were female (84%), mean age=47±12.9 years. The mean follow-up period was 12.6±10.7months. The diffuse cutaneous subset of the disease had 55 pts, limited–37, overlap–11. The mean disease duration was 6.2±5.5years. All pts had ILD. Arterial hypertension was found in 23 pts, dyspnea at inclusion had 88% pts (NYHA 2-3). There was no pts with initial pulmonary artery hypertension. All pts received prednisolone at mean dose of 11.3±4.5 mg/day. 49 pts received immunosuppressants (cyclophosphamide, mycophenolate mofetil in most cases). The cumulative mean dose of RTX was 1.7±0.6 grams. The results are presented in the form of mean values. RESULTS: There was no worsening of cardiac function during RTX therapy. We observed improvement of pulmonary function tests: forced vital capacity % predicted (FVC) increased from 78.7±20 to 82.7±20% (p=0.001), diffusion capacity for carbon monoxide % predicted (DLCO) remains stable (changes from 47.6±18 to 47.3±17%). Diastolic dysfunction of left ventricular was found in 49 pts and did not change on RTX therapy. There was insignificant decrease in the number of pts with cardiac arrhythmias (from 45 to 42) and conduction block (from 42 to 39). Left ventricular ejection fraction (LVEF) was stable (63.1±7%). But there was 5 pts with LVEF≤50%. In this pts LVEF increased from 42.8±10 to 47.8±5.6%. PASP also remains stable in general for the group (34.6±12.1). There was 33 pts with elevated PASP (≥35mmHg by echocardiography). In this pts PASP decreased from 47±13.7 to 44.3±11.5 mmHg (p=0.04). There was a prevalence of pts with elevated PASP in limited compared with diffuse subset of SSc (37.5±17.8 vs 32.2±8.4 mmHg). We found a moderate statistically significant correlation between FVC and PASP (r=-0.411, p=0.001). CONCLUSIONS: In our study, cardiac manifestations were detected almost in half of the pts with ILD-SSc. There was not observed any worsening of cardiac function during RTX therapy. There was significant improvement of LVEF and PASP in pts with an initial disturbance of these parameters. An improvement of LVEF and PASP was accompanied by an increase of FVC and stabilization of DLCO. CLINICAL IMPLICATIONS: RTX could be is an effective and safe treatment option for ILD-SSc with cardiac involvement. DISCLOSURES: No relevant relationships by Lidia Ananyeva No relevant relationships by Oxana Desinova No relevant relationships by Liudmila Garzanova No relevant relationships by Anna Khelkovskaya-Sergeeva No relevant relationships by Olga Koneva No relevant relationships by Olga Ovsyannikova No relevant relationships by Rushana Shayakhmetova No relevant relationships by Mayya Starovoytova" @default.
• W4387248528 created "2023-10-03" @default.
• W4387248528 creator A5040677960 @default.
• W4387248528 creator A5057567181 @default.
• W4387248528 creator A5067055222 @default.
• W4387248528 creator A5072510040 @default.
• W4387248528 creator A5005602506 @default.
• W4387248528 creator A5016657397 @default.
• W4387248528 creator A5043471476 @default.
• W4387248528 creator A5073075511 @default.
• W4387248528 date "2023-10-01" @default.
• W4387248528 modified "2023-10-03" @default.
• W4387248528 title "INTERSTITIAL LUNG DISEASE AND HEART MANIFESTATIONS ASSOCIATED WITH SYSTEMIC SCLEROSIS DURING RITUXIMAB TREATMENT" @default.
• W4387248528 doi "https://doi.org/10.1016/j.chest.2023.07.2037" @default.
• W4387248528 hasPublicationYear "2023" @default.
• W4387248528 type Work @default.
• W4387248528 citedByCount "0" @default.
• W4387248528 crossrefType "journal-article" @default.
• W4387248528 hasAuthorship W4387248528A5005602506 @default.
• W4387248528 hasAuthorship W4387248528A5016657397 @default.
• W4387248528 hasAuthorship W4387248528A5040677960 @default.
• W4387248528 hasAuthorship W4387248528A5043471476 @default.
• W4387248528 hasAuthorship W4387248528A5057567181 @default.
• W4387248528 hasAuthorship W4387248528A5067055222 @default.
• W4387248528 hasAuthorship W4387248528A5072510040 @default.
• W4387248528 hasAuthorship W4387248528A5073075511 @default.
• W4387248528 hasBestOaLocation W43872485281 @default.
• W4387248528 hasConcept C126322002 @default.
• W4387248528 hasConcept C164705383 @default.
• W4387248528 hasConcept C165637977 @default.
• W4387248528 hasConcept C2776694085 @default.
• W4387248528 hasConcept C2776755627 @default.
• W4387248528 hasConcept C2777543607 @default.
• W4387248528 hasConcept C2777714996 @default.
• W4387248528 hasConcept C2779338263 @default.
• W4387248528 hasConcept C2780653079 @default.
• W4387248528 hasConcept C2780930700 @default.
• W4387248528 hasConcept C3018587741 @default.
• W4387248528 hasConcept C55520419 @default.
• W4387248528 hasConcept C71924100 @default.
• W4387248528 hasConcept C75603125 @default.
• W4387248528 hasConcept C90924648 @default.
• W4387248528 hasConceptScore W4387248528C126322002 @default.
• W4387248528 hasConceptScore W4387248528C164705383 @default.
• W4387248528 hasConceptScore W4387248528C165637977 @default.
• W4387248528 hasConceptScore W4387248528C2776694085 @default.
• W4387248528 hasConceptScore W4387248528C2776755627 @default.
• W4387248528 hasConceptScore W4387248528C2777543607 @default.
• W4387248528 hasConceptScore W4387248528C2777714996 @default.
• W4387248528 hasConceptScore W4387248528C2779338263 @default.
• W4387248528 hasConceptScore W4387248528C2780653079 @default.
• W4387248528 hasConceptScore W4387248528C2780930700 @default.
• W4387248528 hasConceptScore W4387248528C3018587741 @default.
• W4387248528 hasConceptScore W4387248528C55520419 @default.
• W4387248528 hasConceptScore W4387248528C71924100 @default.
• W4387248528 hasConceptScore W4387248528C75603125 @default.
• W4387248528 hasConceptScore W4387248528C90924648 @default.
• W4387248528 hasIssue "4" @default.
• W4387248528 hasLocation W43872485281 @default.
• W4387248528 hasOpenAccess W4387248528 @default.
• W4387248528 hasPrimaryLocation W43872485281 @default.
• W4387248528 hasRelatedWork W1938236294 @default.
• W4387248528 hasRelatedWork W2073232449 @default.
• W4387248528 hasRelatedWork W2080404335 @default.
• W4387248528 hasRelatedWork W2169974863 @default.
• W4387248528 hasRelatedWork W2765490201 @default.
• W4387248528 hasRelatedWork W2910170645 @default.
• W4387248528 hasRelatedWork W2972610693 @default.
• W4387248528 hasRelatedWork W3130503360 @default.
• W4387248528 hasRelatedWork W4283697588 @default.
• W4387248528 hasRelatedWork W4376278812 @default.
• W4387248528 hasVolume "164" @default.
• W4387248528 isParatext "false" @default.
• W4387248528 isRetracted "false" @default.
• W4387248528 workType "article" @default.